A marketing application represents years of development and significant investment. Yet the difference between a smooth approval and a frustrating cycle of deficiency letters often comes down to how well the dossier is compiled and published. This article breaks down the eCTD practices that keep submissions out of the rejection pile and accelerate review.
The dossier is a product, not a folder
The most successful regulatory teams treat the eCTD dossier as a deliverable in its own right — one with quality attributes, acceptance criteria and a defined process. A submission is not simply a collection of documents dropped into the Common Technical Document structure; it is a navigable, validated, reviewer-friendly argument for approval.
Reviewers form an impression quickly. A well-structured dossier with accurate hyperlinks, sensible granularity and consistent content signals a capable applicant. A disorganized one invites scrutiny — and questions.
Get the structure and granularity right
The CTD's five modules are familiar, but the details trip teams up:
- Module 1 is region-specific. The administrative and prescribing information differs for FDA, EMA, MHRA and each rest-of-world market. Using the wrong regional Module 1 is a common, avoidable cause of rejection.
- Granularity — how documents are split across the eCTD structure — must follow the agency's specification. Over- or under-splitting makes the dossier harder to navigate and to maintain across its lifecycle.
- Hyperlinking and bookmarking should help a reviewer move from summary to supporting data effortlessly. Broken or absent links are a frequent quality defect.
Validate before you submit
Every eCTD sequence should be technically validated against the relevant agency's specification before it reaches the gateway. Validation tools check the XML backbone, file formats, hyperlink integrity and structure against the agency's validation criteria.
Skipping this step is how avoidable technical rejections happen — a sequence bounced at the gateway costs days or weeks at exactly the moment timelines matter most. A disciplined team treats a clean validation report as a non-negotiable gate.
Lifecycle thinking from sequence one
An initial application is only the first sequence in a product's regulatory life. Variations, renewals and responses will follow for years. The lifecycle operations — how documents are replaced, appended or made new across sequences — must be correct from the start, because errors compound.
Common lifecycle pitfalls include:
- Incorrect lifecycle operators that orphan or duplicate documents.
- Granularity decisions early on that make later variations awkward.
- Loss of sequence tracking across markets, so the current state of a dossier is unclear.
A clear lifecycle plan and rigorous sequence tracking keep the dossier coherent over its whole life.
Content quality still matters most
Publishing excellence cannot rescue weak content. Deficiency letters most often address substance — gaps in the data, inconsistencies between modules, or arguments that do not hold. The quality summaries (Module 2) deserve particular care: they are where reviewers spend much of their time, and inconsistencies between the summary and the detailed data in Modules 3–5 are quickly noticed.
The most effective teams build cross-functional review into the timeline, checking that the CMC, non-clinical and clinical stories are internally consistent before publishing.
Build the process, not just the submission
Right-first-time submissions come from a repeatable process: defined templates, clear authoring standards, publishing checklists, validation gates and lifecycle rules. Whether that capability sits in-house or with a partner, the discipline is what reduces queries and shortens approval timelines.
The takeaway
eCTD success is part craft, part discipline. Use the correct regional structure, respect granularity, validate every sequence, plan for the lifecycle, and never let publishing polish distract from content quality. Get those right and you spend less time answering deficiency letters — and more time on the market.
PharmExpert compiles and publishes compliant eCTD submissions for FDA, EMA, MHRA and ROW markets. Explore our regulatory affairs services.